Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of WG1025 for dystrophic epidermolysis bullosa
CTR20241194Phase 2Active
- Sponsor
- V-Canpharma
- Start
- May 2024
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of WG1025 in dystrophic epidermolysis bullosa (DEB), sponsored by V-Canpharma. Started May 2024; status: active.
02
Drugs
WG1025
03
Conditions
dystrophic epidermolysis bullosa (DEB)
Beyond the preview
Go deeper on CTR20241194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241194.